Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool.
Furosemide
Hospital-acquired acute kidney injury
Nomogram
Prediction
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
02 Sep 2023
02 Sep 2023
Historique:
received:
17
05
2023
accepted:
19
08
2023
medline:
4
9
2023
pubmed:
3
9
2023
entrez:
2
9
2023
Statut:
epublish
Résumé
Furosemide, a frequently prescribed diuretic for managing congestive heart failure and edema, remains a topic of debate regarding its potential risk of inducing acute kidney injury (AKI) in patients. Consequently, this study aims to examine the occurrence of hospital-acquired AKI (HA-AKI) in hospitalized patients who are administered furosemide and to investigate potential risk factors associated with this outcome. This study encompassed a cohort of 22374 hospitalized patients who either received furosemide treatment or not from June 1, 2012, to December 31, 2017. Propensity score matching was employed to establish comparability between the two groups regarding covariates. Subsequently, a nomogram was constructed to predict the probability of AKI occurrence among patients who underwent furosemide treatment. The regression analysis identified the single-day total dose of furosemide as the most significant factor for AKI, followed by ICU administration, estimated glomerular filtration rate, antibiotic, statin, NSAIDs, β-blockers, proton pump inhibitor, chronic kidney disease, and 7 other indicators. Subgroup analysis revealed a synergistic effect of furosemide with surgical operation, previous treatment with β-blockers, ACEI/ARB and antibiotics, leading to an increased risk of AKI when used in combination. Subsequently, a visually represented prognostic nomogram was developed to predict AKI occurrence in furosemide users. The predictive accuracy of the nomogram was assessed through calibration analyses, demonstrating an excellent agreement between the nomogram predictions and the actual likelihood of AKI, with a probability of 77.40%. Careful consideration of factors such as dosage, concurrent medication use, and renal function of the patient is necessary for clinical practice when using furosemide. Our practical prognostic model for HA-AKI associated with furosemide use can be utilized to assist clinicians in making informed decisions about patient care and treatment.
Identifiants
pubmed: 37660080
doi: 10.1186/s40001-023-01306-0
pii: 10.1186/s40001-023-01306-0
pmc: PMC10474726
doi:
Substances chimiques
Furosemide
7LXU5N7ZO5
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
312Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Clin J Am Soc Nephrol. 2022 Aug;17(8):1220-1233
pubmed: 35273009
J Clin Oncol. 2012 Sep 10;30(26):3297-303
pubmed: 22649133
BMJ. 2006 Aug 26;333(7565):420
pubmed: 16861256
N Engl J Med. 2020 Jul 16;383(3):240-251
pubmed: 32668114
Nat Rev Cardiol. 2015 Mar;12(3):184-92
pubmed: 25560378
Lancet. 2019 Nov 23;394(10212):1949-1964
pubmed: 31777389
Intensive Care Med. 2019 Apr;45(4):545-548
pubmed: 30643933
Crit Care. 2020 Mar 4;24(1):75
pubmed: 32131879
J Nephrol. 2019 Dec;32(6):937-945
pubmed: 31243735
J Clin Diagn Res. 2015 Feb;9(2):FC10-3
pubmed: 25859467
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
J Oral Pathol Med. 2020 Oct;49(9):849-856
pubmed: 32449232
Psychol Methods. 2002 Jun;7(2):147-77
pubmed: 12090408
Ann Transl Med. 2016 Jan;4(2):30
pubmed: 26889483
PLoS One. 2015 Jul 06;10(7):e0132507
pubmed: 26146836
Chest. 2019 Sep;156(3):594-603
pubmed: 31002784
J Clin Med. 2022 Jun 24;11(13):
pubmed: 35806949
N Engl J Med. 1995 Mar 9;332(10):647-55
pubmed: 7845430
Nat Rev Mol Cell Biol. 2022 Jan;23(1):40-55
pubmed: 34518686
Kidney Blood Press Res. 2019;44(4):457-464
pubmed: 31362295
Clin J Am Soc Nephrol. 2009 Jul;4(7):1275-83
pubmed: 19520747
Radiology. 1983 Sep;148(3):839-43
pubmed: 6878708
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Nephrology (Carlton). 2013 Mar;18(3):183-7
pubmed: 23336108
Int J Mol Sci. 2021 Sep 23;22(19):
pubmed: 34638575
Blood Purif. 1997;15(4-6):319-22
pubmed: 9435960
Crit Care. 2020 May 25;24(1):253
pubmed: 32450912
Am J Gastroenterol. 2020 Sep;115(9):1505-1512
pubmed: 32371628
J Am Soc Nephrol. 2018 Mar;29(3):1011-1019
pubmed: 29196304
Ann Transl Med. 2017 May;5(10):211
pubmed: 28603726
JAMA. 2013 Dec 18;310(23):2533-43
pubmed: 24247300
Kidney Dis (Basel). 2021 Mar;7(2):143-155
pubmed: 33824870
Circulation. 2018 May 8;137(19):2016-2028
pubmed: 29352071
Clin J Am Soc Nephrol. 2021 Oct;16(10):1601-1609
pubmed: 34462285
Nat Rev Dis Primers. 2021 Jul 15;7(1):52
pubmed: 34267223
Minerva Anestesiol. 2009 May;75(5):251-7
pubmed: 18636060
BMC Nephrol. 2020 May 14;21(1):181
pubmed: 32410656
Drug Saf. 2022 Nov;45(11):1413-1421
pubmed: 36127547
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Eur Heart J. 2014 May 14;35(19):1235-7
pubmed: 24685713
Antioxid Redox Signal. 2017 Feb 10;26(5):221-226
pubmed: 27530232
J Am Soc Nephrol. 2000 Jan;11(1):97-104
pubmed: 10616845
Ren Fail. 2014 Aug;36(7):1051-5
pubmed: 24940940
Health Serv Outcomes Res Methodol. 2012 Jun;12(2-3):219-233
pubmed: 22879799
Intensive Care Med. 2017 Jun;43(6):855-866
pubmed: 28466146
Ann Transl Med. 2021 Mar;9(5):400
pubmed: 33842621
Ann Intern Med. 2016 May 3;164(9):W42-7
pubmed: 27136231
Kidney Int. 2000 May;57(5):2080-3
pubmed: 10792627
N Engl J Med. 2019 May 30;380(22):2146-2155
pubmed: 31141635
Clin J Am Soc Nephrol. 2011 May;6(5):966-73
pubmed: 21393482
Crit Care. 2018 Aug 19;22(1):202
pubmed: 30121080
Anaesthesia. 2018 Feb;73(2):238-247
pubmed: 28940440